An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

Phase 2 Enrolling by invitation 94 enrolled Xentria, Inc.

NaSingle-groupOpen-labelTreatment

Summary

Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement

Timeline

Start: 2024-03-01
Primary completion: 2029-01
Completion: 2029-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	XTMAB-16	Unknown	—	Other

An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

Summary

Timeline

Drugs

Indications